home / stock / hoth / hoth news


HOTH News and Press, Hoth Therapeutics Inc. From 04/19/21

Stock Information

Company Name: Hoth Therapeutics Inc.
Stock Symbol: HOTH
Market: NASDAQ
Website: hoththerapeutics.com

Menu

HOTH HOTH Quote HOTH Short HOTH News HOTH Articles HOTH Message Board
Get HOTH Alerts

News, Short Squeeze, Breakout and More Instantly...

HOTH - Shares of Hoth Therapeutics Inc. (HOTH) Have Fallen Below Previous 52-Week Low

Hoth Therapeutics Inc. (NASDAQ:HOTH) traded today at a new 52-week low of $1.50. Approximately 14.2 million shares have changed hands today, as compared to an average 30-day volume of 4.1 million shares. There is potential upside of 27.6% for shares of Hoth Therapeutics Inc. based on a c...

HOTH - Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation to Congressional Offices and Agencies, Including HHS, NIH, FDA, and DoD

NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on Thursday April 8th. This follows dozens of recent one-on-one briefings with Congressional staf...

HOTH - Hoth Therapeutics completes HT-001 formulation development for upcoming cancer trial

Hoth Therapeutics (HOTH) has completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies.HT-001 is expected to start its Phase 2a trial in pending approval of the IND submission.The finalization...

HOTH - Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial

Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial PR Newswire NEW YORK , April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, toget...

HOTH - Hoth Therapeutics engages worldwide clinical trials for mid-stage HT-001 trial

Hoth Therapeutics ([[HOTH]] -5.6%) announces that it has engaged a full-service contract research organization Worldwide Clinical Trials for its upcoming Phase 2a dose ranging clinical trial of HT-001 for treatment of cutaneous toxicities associated with EGFR inh...

HOTH - Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients

Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients PR Newswire NEW YORK , April 6, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biop...

HOTH - TSLA, NVTA, CHPT and NNOX among premarket gainers

Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...

HOTH - Hoth issued notice of allowance for biofilms inhibition patent application

Hoth Therapeutics (HOTH) announces that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the company's method for inhibiting formation of biofilms.Biofilms are types of microorganisms that can grow on different surfaces.Shares up nearly 5%&...

HOTH - Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm PR Newswire NEW YORK , April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused cli...

HOTH - Aptose Biosciences, Brainstorm Cell Therapeutics leads healthcare gainers; Benitec Biopharma, Second Sight Medical Products among major losers

Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -1...

Previous 10 Next 10